Creative Approaches to Improving Access To

CREATIVE APPROACHES TO IMPROVING ACCESS TO MEDICINES GLOBALLY Dr Bernard Pécoul, DNDi Executive Director 3 December 2019, 10:00 - 17:00 Auditorium Ivan Pictet, Maison de la Paix, Geneva

www.dndi.org CREATIVE APPROACHES TO IMPROVING ACCESS TO MEDICINES GLOBALLY, 3 DECEMBER 2019, GENEVA 2

Abundant R&D pipeline for HCV PHASE 1 in 2015… but many drug EDP-494 chlorcyclizine JNJ-47910382 BL-8020 PHASE candidates abandoned AVR-560 TT-034 2 PPI-461 AV-4025 H-5C alisporivir ITX-5061 odalasvir MB-110 RG-101 (ACH-3102) SCY-635 PHASE EDP-239 BIT225 3 velpatasvir samatasvir miravirsen (GS-5816) (IDX-719) ombitasvir ABT-530 MK-8408 daclatasvir FDA elbasvir ravidasvir GS-9857 paritaprevir Approval ledipasvir grazoprevir sovaprevir ABT-493 simeprevir sofosbuvir danoprevir asunaprevir dasabuvir ACH-3422 furaprevir MK-3682 (TG-2349) (formerly faldaprevir IDX21437) AL-335 MK-1075 GSK- 2878175

MK-8876

PPI-383

www.dndi.org 3 CREATIVE APPROACHES TO IMPROVING ACCESS TO MEDICINES GLOBALLY, 3 DECEMBER 2019, GENEVA DNDi Hepatitis C Strategy: 3 pillars

3 1 2 Simplify Accelerate Catalyse TREATMENT R&D ACCESS STRATEGIES

Accelerating the Working with health Supporting affordable providers to scale –up development of access to all DAAs ravidasvir treatment

with with with Pharma Pharma Primary companies companies healthcare Civil Society doctors Governments organisations Non Governmental Governments Organizations

www.dndi.org 4 CREATIVE APPROACHES TO IMPROVING ACCESS TO MEDICINES GLOBALLY, 3 DECEMBER 2019, GENEVA Public Interest R&D partnerships: affordable treatments

www.dndi.org 5 CREATIVE APPROACHES TO IMPROVING ACCESS TO MEDICINES GLOBALLY, 3 DECEMBER 2019, GENEVA Voluntary Licences exclude more than 25 percent of HCV infected people in MICs

www.dndi.org 6 CREATIVE APPROACHES TO IMPROVING ACCESS TO MEDICINES GLOBALLY, 3 DECEMBER 2019, GENEVA DAAs prices depend on IP status and Government leadership (prices in US$ per 12 weeks) 35'000 Sofosbuvir + daclatasvir $30.000 30'000 Sofosbuvir + velpatasvir Glecaprevir + pibrenstavir DAAs combination/product not specified 25'000

20'000 $18.380 $16.300

15'000

Generic DAAs 10'000 $7.900 $7.352

5'000 $4.050

$990 1233 $41 $70 $75 $78 $90 $102 $300 0

www.dndi.org 7 CREATIVE APPROACHES TO IMPROVING ACCESS TO MEDICINES GLOBALLY, 3 DECEMBER 2019, GENEVA Only 5 million people treated in 2013-2017 worldwide

1.8M people treated 2.5M people treated 0.7M people treated

66M people remain to be treated by 2030

www.dndi.org 8 CREATIVE APPROACHES TO IMPROVING ACCESS TO MEDICINES GLOBALLY, 3 DECEMBER 2019, GENEVA Simplification of HCV model of care will be critical to detect and treat 80% of patients still unaware of their status

www.dndi.org 9

THANK YOU FOR YOUR ATTENTION